Table 4.
Mean | Number of event cases | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Country | Study | Cohort size | Exposure period |
Follow-up period |
cumulative dose (mSv) |
Person years |
Types of events | ERR (95% CI) |
SMR or SIR (95% CI) | |
15-country | Cardis et al. (2007) [23] | 407,391 | 1943-2000 | 1943-2000 | 19.4 | 5,192,710 | Mortality | 196 | 1.93 b(<0, 7.14) |
- |
3-country (INWORKS) |
Leuraud et al. (2015) [24] | 308,297 | 1943-2005 | 1944-2005 | 15.9mGy | 8,220,000 | Mortality | 531 | 2.96 (1.17, 5.21) | - |
Korea | aAhn et al. (2008) [64] | 79,679 | 1984-2004 1984-2004 |
1992-2004 1989-2005 |
6.1 6.1 |
633.159 415,298 |
Mortality Morbidity |
9 14 |
16.8 b(-34, 149) 15.8 b(-31, 108) |
0.59 (0.28, 1.06) |
Jeong et al. (2010) [65] | 8,429 | 1978-2005 | 1992-2005 | 19.86 | 63,503 | Incidence | 3 | NC | 1.34 (0.27, 3.92) | |
U.K. | Muirhead et al. (2009) [63] | 174,541 | 1946-2001 | 1965-2001 | 24.9 | 3,900,000 | Mortality Incidence |
198 234 |
1.71 (-0.17, 4.92) 1.78 (-0.06, 4.99) | 0.89 (0.76, 1.03) |
U.S. | Howe et al. (2004) [66] | 53,698 | Mid-1960s | 1979-1997 | 25.7 | 698,051 | Mortality | 26 | 5.67 (-2.56, 30.4) | a 1.07 (0.71, 1.53) |
Canada | Zablotska et al. (2014) [67] | 45,316 | 1951-1994 | 1956-1994 | 21.64 | 613,648 | Mortality | 17 | 9.79 (<-1.49, 107) | 0.78 (0.45, 1.25) |
France | Flamant et al. (2013) [30] | 59,021 | 1950-2004 | 1968-2004 | 16.1 | 1,467,611 | Mortality | 60 | 3.96 b(<0, 16.82) |
- |
Germany | Merzenich et al. (2014) [68] | 8,972 | 1966-2008 | 1991-2008 | 29.5 | 130,737 | Mortality | 7 | - | 1.19 (0.41, 2.75) |
aJapan | Akiba et al. (2012) [28] | 200,583 | 1977-2002 | 1991-2002 | 12.2 | 1,373,000 | Mortality | 80 | -1.93 (-6.12, 8.57) | - |
Russia | Shilnikova et al. (2003) [25] | 21,557 | 1948-1997 | 1948-1997 | 810 mGy | 720,000 | Mortality | 66 | 1 b(0.5, 2) |
- |
a all leukemia; b 90% CI; NC was no convergence of deviance after maximum iteration. CLL, chronic lymphocytic leukemia